Abstracts Archive - Page 1081 of 2607 - ACR Meeting Abstracts

Abstract Number: 2114 • 2019 ACR/ARP Annual Meeting
Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Daisuke Kobayashi¹, Sayuri Takamura ², Yoko Wada ³, Takeshi Kuroda ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, ³Niigata Rinko Hospital, Niigata, Niigata, Japan, ⁴Health administration office, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections.…
Abstract Number: 2115 • 2019 ACR/ARP Annual Meeting
BK Polyomavirus Viremia and Viruria in Patients with Autoimmune Connective Tissue Diseases: Impact of Immunosuppressants
Mamatha Katikaneni¹, Madeline Davis ¹, Carolyn Smith ² and John Vanchiere ², ¹LSUHSC- Shreveport, Shreveport, LA, ²LSUHSC- Shreveport, Shreveport
Background/Purpose: The human polyomaviruses, such as the BK and JC virus, are highly prevalent in humans but appear to cause clinical disease only in immunocompromised…
Abstract Number: 2116 • 2019 ACR/ARP Annual Meeting
Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
Lisa Lindsay¹, Ching-Yi Chuo ², Nicholas Jones ², Joshua Galanter ², Anna McGregor ² and Katie Tuckwell ², ¹Genentech Inc, SOUTH SAN FRANCISCO, CA, ²Genentech Inc, SOUTH SAN FRANCISCO
Background/Purpose: Patients with systemic lupus erythematosus (SLE), lupus nephritis (LN) and rheumatoid arthritis (RA) are at risk of serious infections (SIs) due to the impact…
Abstract Number: 2117 • 2019 ACR/ARP Annual Meeting
Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis
DOROTHEE VINSON¹, LUC MOLLET-BENHAMOU ², Yannick Degboe ³, Thao Pham ⁴, Thomas BARNETCHE ⁵, Arnaud Constantin ⁶ and Adeline Ruyssen-Witrand ⁷, ¹AP-HM CHU Marseille, Marseille, France, ²CHU Toulouse, Toulouse, France, ³University of Glasgow, Glasgow, United Kingdom, ⁴Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ⁵CHU Bordeaux, Toulouse, France, ⁶CHU TOUOUSE, TOULOUSE, France, ⁷Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France
Background/Purpose: A previous meta-analysis1 showed that tapering of bDMARDs does not increase the risk of relapse in rheumatoid arthritis (RA) patients with remission or low…
Abstract Number: 2118 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis
Yushiro Endo¹, Kunihiko Umekita ², Hideki Nakamura ¹, Shoichi Fukui ³, Takahisa Suzuki ⁴, Junya Miyamoto ⁵, Toshimasa Shimizu ¹, Tomohiro Koga ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Tomoki Origuchi ⁶, Akitomo Okada ⁷, Keita Fujikawa ⁸, Akinari Mizokami ⁸, Naoki Matsuoka ⁹, Toshiyuki Aramaki ¹⁰, Yukitaka Ueki ¹⁰, Katsumi Eguchi ¹⁰, Yumi Kariya ², Yayoi Hashiba ¹¹, Toshihiko Hidaka ¹¹, Akihiko Okayama ² and Atsushi Kawakami ¹², ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²University of Miyazaki, Miyazaki, Japan, ³Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Nagasaki, Japan, ⁴Sasebo City General Hospital, Sasebo, Japan, ⁵Nagasaki University Hospital Clinical Research Center, Nagasaki, Japan, ⁶Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁷Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁸JCHO Isahaya General Hospital Department of Rheumatology, Isahaya, Japan, ⁹Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ¹⁰Sasebo Chuo Hospital Rheumatic and Collagen Disease Center, Sasebo, Japan, ¹¹Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ¹²Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: The asymptotic individuals with the human T lymphotropic virus type I (HTLV-I) infection rarely develop adult T cell leukemia/lymphoma (ATL) or HTLV-I–associated myelopathy (HAM).…
Abstract Number: 2119 • 2019 ACR/ARP Annual Meeting
Impact of Day of Admission and Time to Diagnostic Arthrocentesis on Mortality and Other Outcomes in Septic Arthritis: A Nationwide Analysis
Gustavo Contreras¹, Ana B Arevalo ¹, Shane Murray ¹, Faris Haddadin ¹ and Yiming Luo ¹, ¹Mount Sinai St. Luke's - West/ Icahn School of Medicine, New York, NY
Background/Purpose: Multiple studies have been done assessing the “weekend effect” and outcomes for hospitalized patients 1,2,3,4, however, there is no data evaluating the outcome of…
Abstract Number: 2120 • 2019 ACR/ARP Annual Meeting
No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study
Xintong Li ¹, Kathleen M Andersen², Hsien-Yen Chang ³, G. Caleb Alexander ⁴ and Jeffrey Curtis ⁵, ¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, ⁴Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The real-world risk of serious infections associated with interleukin (IL) and tumor necrosis factor-alpha (TNF-α) inhibitors for patients with psoriasis (PsO) and psoriatic arthritis…
Abstract Number: 2121 • 2019 ACR/ARP Annual Meeting
Hospitalization Trends for Bacterial Septic Arthritis in the United States from 1997 to 2014
Soumyasri Kambhatla¹, Estefania Gauto-Mariotti ² and AUGUSTINE MANADAN ³, ¹John H. Stroger Hospital of Cook County, Chicago, ²Cook County Health, chicago, ³Rush University Medical Center, chicago
Background/Purpose: Bacterial septic arthritis is a serious cause of morbidity and mortality, constituting one of the true musculoskeletal emergencies. In this abstract, we describe hospitalization…
Abstract Number: 2122 • 2019 ACR/ARP Annual Meeting
Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions
Soumyasri Kambhatla¹, Estefania Gauto-Mariotti ² and Augustine Manadan ³, ¹John H. Stroger Hospital of Cook County, Chicago, ²John H Stroger Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Septic arthritis is known to cause significant morbidity due to joint destruction and mortality if timely and adequate treatment is not given. In this study,…
Abstract Number: 2123 • 2019 ACR/ARP Annual Meeting
Clinical Features of Prosthetic Joint Infections in Patients with Rheumatic Diseases vs Osteoarthritis
Susan Goodman¹, Milan Kapadia ², Andy Miller ², Laura Donlin ³, Michael Henry ², Linda Russell ², Mark Figgie ⁴, Allina Nocon ² and Peter Sculco ², ¹Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Rheumatic disease (RD) patients are at increased risk for prosthetic joint infections (PJI), however, diagnosis is challenging because active RD may mimic joint infection…
Abstract Number: 2124 • 2019 ACR/ARP Annual Meeting
Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?
Ariana Ringer¹, Juan Pablo Ruffino ², Nadia Cuadranti ², Ignacio Rolla ², Juan Manuel Vandale ², Carla Achilli ², Cecilia Argento ², Florencia Martinez ², Noel Cortese ², Mariano Palatnik ², Mariana Lagrutta ³, Rodolfo Leiva ⁴, Damian Aguila ⁵, Maria Jose Svetaz ⁶, Laura Cordoba ⁷, Milagros Zafra ⁸, Telma Gambander ⁸, Patricia Sciarrata ⁶, Silvina Villar ⁹, Florencia Gonzalez ⁹, Florencia Pacini ⁹, Ana Rosa Perez ⁹, Oscar Bottasso ⁹ and Marcelo Abdala ², ¹Rheumatology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Totoras, Santa Fe, Argentina, ²Rheumatology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ³Internal Medicine. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ⁴Cardiology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ⁵Infectology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ⁶Central Laboratory. UNR, Rosario, ⁷Microbiology, Rosario, ⁸Microbiology. UNR, Rosario, ⁹Immunology. IDICER, CONICET, UNR, Rosario
Background/Purpose: American Trypanosomiasis or Chagas Disease (CD) is a zoonotic infection, endemic in Latin America. It is a major cause of morbidity, mortality and economic…
Abstract Number: 2125 • 2019 ACR/ARP Annual Meeting
Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
mohammad hammad saied¹, Liora Harel ², Gil Amarilyo ³, rotem tal ⁴ and Razi Zidani ⁵, ¹schneider medical center, kaboul village, Israel, ²Tel Aviv University, Tel Aviv, Israel, ³schneider medical center, petach tekva, ⁴schneider medical center, ramat gan, Israel, ⁵tel aviv university, Tamra, Israel
Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
Abstract Number: 2126 • 2019 ACR/ARP Annual Meeting
Combined Detection of Cytokines and Biomarkers Improve the Diagnostic Performance of Bacteria Infection in Rheumatoid Arthritis
Yan Qin¹, Xiangcong Zhao ¹ and Jing Luo ¹, ¹the Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic)
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer a high susceptibility to infection, and many inflammatory cytokines are prognostic in RA, but currently the role of cytokines in identifying infection individuals…
Abstract Number: 2127 • 2019 ACR/ARP Annual Meeting
Diagnosis of Inflammatory Rheumatic Diseases: Preliminary Approach by Urine Metabolomics
Judit Morello ¹, Sara M. Teixeira ¹, João Rodrigues ², Sara Maia ³, Atlas Sardoo ⁴, Rita Pinheiro Torres ⁵, Sofia A. Pereira ⁴, Jaime Branco ⁶, Alexandra Antunes ⁷ and Fernando Pimentel-Santos⁴, ¹Centro de Química Estrutural, Instituto Superior Técnico, Ulisboa, Lisboa, Portugal, ²Clarify Analytical, Évora, Portugal, ³CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal, ⁴Centro de Estudos de Doenças Crónicas (CEDOC), Nova Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal, lisboa, Portugal, ⁵Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ⁶CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ⁷Centro de Química Estrutural, Instituto Superior Técnico, Ulisboa,, Lisboa, Portugal
Background/Purpose: Early diagnosis of inflammatory rheumatic diseases (IRD), as axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) represents in our days a…
Abstract Number: 2128 • 2019 ACR/ARP Annual Meeting
Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality
Dipekka Soni¹, David Maniscalco ², Srihari Veeraraghavan ³, Justin Cheeley ³ and Arezou Khosroshahi ¹, ¹Emory University, Atlanta, GA, ²Emory University, Altanta, ³Emory University, Atlanta
Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].